<DOC>
	<DOCNO>NCT01747538</DOCNO>
	<brief_summary>The purpose study evaluate efficacy gevokizumab reduce risk recurrent uveitic disease subject non-infectious uveitis whose disease currently control systemic treatment .</brief_summary>
	<brief_title>Safety Efficacy Study Gevokizumab Treat Non-infectious Uveitis Controlled With Systemic Treatment</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<criteria>Diagnosis noninfectious intermediate , posterior , pan uveitis least one eye Controlled uveitic disease eye Stable dose oral corticosteroid combination select stable immunosuppressive therapy Effective contraceptive measure Infectious uveitis masquerade syndrome Isolated anterior uveitis Contraindication mydriatic Active tuberculosis disease History allergic anaphylactic reaction monoclonal antibody History recurrent infection predisposition infection ; active ocular infection Pregnant nursing woman Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Uveitis</keyword>
	<keyword>Non-infectious Uveitis</keyword>
	<keyword>Intermediate Uveitis</keyword>
	<keyword>Posterior Uveitis</keyword>
	<keyword>Panuveitis</keyword>
</DOC>